As reported at the American Society of Hematology (ASH) 2025 Annual Meeting, the AMMO trial, delivered at the NIHR King’s Clinical Research Facility and treating almost a quarter of all patients, has shown novel results for people with rare blood cancers.
Funded by Blood Cancer UK, AMMO is a phase 2 UK multicentre trial comparing oral chemotherapy (ASTX727) for five days a month to a medication called hydroxycarbamide in patients with Chronic myelomonocytic leukemia (CMML) and other MDS/MPN overlap syndromes.
These cancers have very limited treatment options and ASTX727 is the first drug in 30 years to show a survival benefit in these patients.
Dr Austin Kulasekararaj, Consultant Haematologist at King’s College Hospital NHS Foundation Trust, said:
We are thrilled with the positive results of the AMMO trial, which demonstrate the importance of delivering clinical trials for our patients with rare blood cancers. We are proud of the contributions of King’s patients and our Clinical Research Facility staff to this important study.